Početna stranicaEKSO • NASDAQ
add
Ekso Bionics Holdings Inc
Preth. zaklj. cijena
0,69 $
Dnevni raspon
0,67 $ - 0,72 $
Godišnji raspon
0,66 $ - 3,13 $
Tržišna kapitalizacija
14,96 mil. USD
Prosječna količina
108,02 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Prihod | 4,13 mil. | −10,38 % |
Operativni troškovi | 4,85 mil. | −10,01 % |
Neto dohodak | −2,07 mil. | 38,42 % |
Neto profitabilnost | −50,18 | 31,30 % |
Zarada po dionici | — | — |
EBITDA | −2,23 mil. | 10,97 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 8,29 mil. | −16,55 % |
Ukupna imovina | 29,21 mil. | −6,33 % |
Ukupne obveze | 14,34 mil. | −9,96 % |
Ukupni kapital | 14,87 mil. | — |
Dionice u optjecaju | 22,00 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 1,02 | — |
Povrat imovine | −23,48 % | — |
Povrat kapitala | −33,02 % | — |
Tok novca
Neto promjena novca
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | −2,07 mil. | 38,42 % |
Gotovina od poslovanja | −2,28 mil. | 32,09 % |
Gotovina iz ulaganja | −8,00 tis. | 52,94 % |
Gotovina iz financiranja | 4,69 mil. | — |
Neto promjena novca | 2,41 mil. | 171,42 % |
Slobodan tok novca | −1,11 mil. | 57,80 % |
Više
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
Glavni izvršni direktor
Osnovano
2005
Web-lokacija
Zaposlenici
70